49.59

2.04% -1.00

Crispr Therapeutics Ag (CRSP)

Overview News Price History Option Chain Financials Why CRSP Down? Discussions Forecast

Crispr Therapeutics Ag stock is traded at $49.59, with a volume of 1.35M. It is down -2.04% in the last 24 hours and up +9.24% over the past month. Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.

Previous Close:

$50.59

Open:

$49.345

24h Volume:

1.35M

Relative Volume:

1.23

Market Cap:

$4.21B

Revenue:

$170.10M

Net Income/Loss:

$-153.61M

P/E Ratio:

-11.09

EPS:

-4.47

Net Cash Flow:

$-272.35M

1W Performance:

+1.27%

1M Performance:

+9.24%

6M Performance:

-11.33%

1Y Performance:

-2.80%

1-Day Range:

$47.04

$49.67

1-Week Range:

$46.30

$51.90

52-Week Range:

$43.42

$91.10

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Name

Crispr Therapeutics Ag

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(617) 315-4600

Address

BAARERSTRASSE 14, ZUG

Employee

407

Twitter

@crisprtx

Next Earnings Date

2024-12-05

Latest SEC Filings

CRSP's Discussions on Twitter

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-11-23	Downgrade	TD Cowen	Market Perform → Underperform
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-27-23	Initiated	Mizuho	Buy
Aug-17-23	Upgrade	Citigroup	Neutral → Buy
May-30-23	Initiated	William Blair	Outperform
Apr-13-23	Initiated	Cantor Fitzgerald	Overweight
Mar-21-23	Initiated	Bernstein	Mkt Perform
Mar-17-23	Initiated	Bryan Garnier	Buy
Mar-07-23	Initiated	Robert W. Baird	Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Aug-09-22	Downgrade	Barclays	Overweight → Equal Weight
Jun-23-22	Downgrade	Evercore ISI	Outperform → In-line
Jun-17-22	Initiated	BMO Capital Markets	Outperform
Apr-28-22	Initiated	Credit Suisse	Neutral
Dec-07-21	Initiated	Cowen	Market Perform
Oct-19-21	Initiated	SVB Leerink	Outperform
Jun-14-21	Upgrade	Citigroup	Sell → Neutral
Apr-21-21	Upgrade	Jefferies	Hold → Buy
Mar-04-21	Initiated	JMP Securities	Mkt Outperform
Dec-10-20	Reiterated	Chardan Capital Markets	Buy
Dec-10-20	Downgrade	Jefferies	Buy → Hold
Dec-10-20	Reiterated	Needham	Buy
Dec-07-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-23-20	Initiated	RBC Capital Mkts	Sector Perform
Oct-05-20	Initiated	BofA Securities	Buy
Jul-28-20	Reiterated	Needham	Buy
Jul-14-20	Initiated	SunTrust	Buy
Jun-15-20	Reiterated	Canaccord Genuity	Buy
Mar-05-20	Initiated	Stifel	Hold
Feb-03-20	Downgrade	Evercore ISI	Outperform → In-line
Nov-19-19	Upgrade	William Blair	Mkt Perform → Outperform
Nov-12-19	Upgrade	Oppenheimer	Perform → Outperform
Aug-01-19	Initiated	Jefferies	Buy
Jul-26-19	Initiated	Canaccord Genuity	Buy
Jun-10-19	Initiated	ROTH Capital	Buy
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-14-19	Initiated	William Blair	Mkt Perform
Jan-28-19	Downgrade	Goldman	Buy → Neutral
Jan-22-19	Downgrade	Citigroup	Neutral → Sell

View All

Crispr Therapeutics Ag Stock (CRSP) Latest News

09:05 AM

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire

09:05 AM

09:01 AM

CRISPR Therapeutics AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

09:01 AM

Nov 04, 2024